Thursday, November 18, 2010

Actelion, Eyed by Amgen, May Fetch $9.8 Billion in Takeover, Analysts Say - Bloomberg

An acquisition would be the biggest purchase of a European biotechnology company since Merck KGaA bought Serono SA for 10.3 billion euros ($14 billion) in 2007, according to data compiled by Bloomberg. Actelion gets most of its sales from Tracleer, a drug to treat a lung condition known as pulmonary arterial hypertension that begins to lose patent protection in five years. The company also has two other compounds to treat the illness in late-stage testing.

Posted via email from Jack's posterous

No comments: